Gilead Sciences GILD Business Segments — Selling and marketing expenses

Similar metrics at other companies

ROLReportable Segment — Selling and marketing expenses

$151.97M+8.4%

SMP

SMPEngineered Solutions — Selling and marketing expenses

$1.99M+3.3%

SMP

SMPNissens Automotive — Selling and marketing expenses

$5.26M+90.4%

SMP

SMPTemperature Control — Selling and marketing expenses

$3.67M-12.6%

SMP

SMPVehicle Control — Selling and marketing expenses

$12M-2.7%

JYNTFranchise Operations — Selling and marketing expenses

$3.72M+6.0%

FAQ

What is Gilead Sciences's business segments — selling and marketing expenses?

Gilead Sciences (GILD) reported business segments — selling and marketing expenses of $1.01B in Q2 2026.

How has Gilead Sciences's business segments — selling and marketing expenses changed year-over-year?

Gilead Sciences's business segments — selling and marketing expenses increased by 17.0% year-over-year, from $864M to $1.01B.

What is the long-term trend for Gilead Sciences's business segments — selling and marketing expenses?

Over 3 years (2022 to 2025), Gilead Sciences's business segments — selling and marketing expenses has grown at a 1.9% compound annual growth rate (CAGR), from $3.33B to $3.52B.

What does business segments — selling and marketing expenses mean?

This metric represents the costs incurred by the company to promote, advertise, and sell its pharmaceutical products to healthcare providers and institutions. It encompasses expenses related to sales force compensation, marketing campaigns, and product launch activities. Monitoring these costs helps assess the company's investment in commercializing its therapeutic portfolio and maintaining market share.